DE60035676D1 - Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer - Google Patents

Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer

Info

Publication number
DE60035676D1
DE60035676D1 DE60035676T DE60035676T DE60035676D1 DE 60035676 D1 DE60035676 D1 DE 60035676D1 DE 60035676 T DE60035676 T DE 60035676T DE 60035676 T DE60035676 T DE 60035676T DE 60035676 D1 DE60035676 D1 DE 60035676D1
Authority
DE
Germany
Prior art keywords
manufacture
lentiviral vectors
recombinant high
titan
safe recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035676T
Other languages
English (en)
Other versions
DE60035676T2 (de
Inventor
Luigi Naldini
Thomas Dull
Anatoly Bukovsky
Deborah Farson
Rochelle Witt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of DE60035676D1 publication Critical patent/DE60035676D1/de
Publication of DE60035676T2 publication Critical patent/DE60035676T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60035676T 1999-04-29 2000-04-26 Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer Expired - Lifetime DE60035676T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13167199P 1999-04-29 1999-04-29
US131671P 1999-04-29
PCT/US2000/011097 WO2000066759A1 (en) 1999-04-29 2000-04-26 Method and means for producing high titer, safe, recombinant lentivirus vectors

Publications (2)

Publication Number Publication Date
DE60035676D1 true DE60035676D1 (de) 2007-09-06
DE60035676T2 DE60035676T2 (de) 2008-04-30

Family

ID=22450511

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035676T Expired - Lifetime DE60035676T2 (de) 1999-04-29 2000-04-26 Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer

Country Status (9)

Country Link
US (2) US7250299B1 (de)
EP (2) EP1849873B1 (de)
JP (1) JP4979851B2 (de)
AT (2) ATE528406T1 (de)
AU (1) AU778698B2 (de)
CA (1) CA2370103C (de)
DE (1) DE60035676T2 (de)
IL (1) IL146144A0 (de)
WO (1) WO2000066759A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20020037281A1 (en) * 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
EP1395293B1 (de) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
AU2008314485B9 (en) 2007-10-15 2015-02-26 Jingang Medicine (Australia) Pty Ltd Expression system for modulating an immune response
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
CA2858980A1 (en) * 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
IN2014DN10408A (de) 2012-06-05 2015-08-14 Univ Australian
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2014214850C1 (en) 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
JP6754761B2 (ja) 2014-07-11 2020-09-16 セルジーン コーポレイション Ｔリンパ球へのベクター導入効率の改善方法
KR20220150428A (ko) 2014-08-12 2022-11-10 안트로제네시스 코포레이션 림프절 b 세포 구역, 피부, 또는 위장관으로 귀소하도록 조작된 car-t 림프구
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
LT3411478T (lt) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimizuoti viii faktoriaus genai
EP3443001A4 (de) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US11331380B2 (en) 2016-10-20 2022-05-17 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
WO2021072129A2 (en) 2019-10-08 2021-04-15 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN115247190B (zh) * 2021-04-28 2024-06-18 沛尔生技医药股份有限公司 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
TWI758171B (zh) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法
CA3223636A1 (en) 2021-08-06 2023-02-09 Christopher Walton CARROLL Compositions and methods for selective degradation of engineered proteins
WO2023023491A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
FR2629469B1 (fr) 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
AU671101B2 (en) * 1992-02-28 1996-08-15 Syngenix Limited Defective packaging non-oncoviral vectors based on MPMV
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6051427A (en) 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0759471A4 (de) * 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co Rekombinanter vektor bestehend aus dem menschlichen immunschwäche-virus und verfahren zu seiner herstellung
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0863988A1 (de) 1995-11-28 1998-09-16 Clinical Technologies, Inc. Rekombinantes hiv und modifizierte verpackungszellen sowie methode zur behandlung von aids
US5750383A (en) * 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system
JP2001501815A (ja) * 1996-09-17 2001-02-13 ザ ソールク インスチチュート フォア バイオロジカル スタディズ 非分裂細胞への形質導入が可能なレトロウイルスベクター
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
DE69703974T2 (de) * 1996-10-17 2001-07-19 Oxford Biomedica Ltd Retrovirale vektoren
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
EP1003894A2 (de) * 1997-07-18 2000-05-31 Chiron Corporation Lentivirale vektoren
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999036511A2 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
CA2328404C (en) * 1998-05-13 2007-07-24 Genetix Pharmaceuticals, Inc. Novel lentiviral packaging cells

Also Published As

Publication number Publication date
CA2370103A1 (en) 2000-11-09
JP4979851B2 (ja) 2012-07-18
US8652837B2 (en) 2014-02-18
IL146144A0 (en) 2002-07-25
AU4489700A (en) 2000-11-17
ATE368122T1 (de) 2007-08-15
US20080241929A1 (en) 2008-10-02
DE60035676T2 (de) 2008-04-30
EP1849873A1 (de) 2007-10-31
EP1849873B1 (de) 2011-10-12
EP1171624B1 (de) 2007-07-25
EP1171624A1 (de) 2002-01-16
ATE528406T1 (de) 2011-10-15
US7250299B1 (en) 2007-07-31
CA2370103C (en) 2011-08-02
WO2000066759A1 (en) 2000-11-09
EP1171624A4 (de) 2002-06-26
JP2003508017A (ja) 2003-03-04
AU778698B2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
DE60035676D1 (de) Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
DE69838758D1 (de) Verfahren und mittel zur herstellung von sicheren, rekombinanten lentivirusvektoren mit hohem titer
DE69302342D1 (de) Wiedergewinnung von Ethylen bei Direkt-Oxidations-Verfahren zur Herstellung von Ethylenoxid
DE59002517D1 (de) Presslinge auf Basis von pyrogen hergestelltem Siliciumdioxid, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE69203229D1 (de) Verfahren zur herstellung von wiederaufladbarem abgeändertem mangandioxid-material und ähnliche verbindungen sowie elektrodenmaterial.
DE69406559T2 (de) Integriertes Verfahren zur Herstellung von Brenngas und Sauerstoff enthaltenden organischen Produkten
DE69007639D1 (de) Silberkatalysator zur Produktion von Ethylenoxid und Verfahren zur Herstellung davon.
DE59804783D1 (de) Eisenoxidrotpigmente, Verfahren zur Herstellung von Eisenoxidrotpigmenten und deren Verwendung
DE3853220D1 (de) Verfahren und Gerät zur Herstellung von Produkten.
DE69627839D1 (de) Caseinphosphopeptide und dasselbe enthaltende casein, sowie verfahren in dessem herstellung
NO911942D0 (no) Bleke- og oksydasjonskatalysator, blekeprosess samt blekeblanding.
DE68912909D1 (de) Verfahren zur Herstellung von Nitrilen und Oxiden.
DE68907447D1 (de) Geblasene, einstueckige flasche und verfahren zur herstellung derselben.
DE69606255D1 (de) Verfahren zur herstellung von fällungskieselsäure, zinkenthaltenden fällungskieselsäuren und deren verwendung zur verstärkung von elastomeren
DE59804784D1 (de) Eisenoxidgelbpigmente, Verfahren zur Herstellung von Eisenoxidgelbpigmenten und deren Verwendung
ATE71297T1 (de) Feste arzneizubereitungen mit dihydropyridin und verfahren zu ihrer herstellung.
DE59101232D1 (de) Verfahren und Mittel zur Herstellung von Bohrungen.
DE3878855D1 (de) Verfahren zur herstellung von granulat aus titanoxid, zirkoniumoxid oder ceroxid und produkte daraus.
DE3861709D1 (de) Anti-hiv-mittel und methode zu deren erzeugung.
DE59404875D1 (de) Verfahren zur Herstellung von Verbundgegenständen aus Polyestern und Elastomeren
DE68922042D1 (de) Verfahren zur Herstellung von Titanoxid.
DE3761356D1 (de) Verfahren und extrusionsblasmaschine zur herstellung von flachflaschen.
DE69101971D1 (de) Anorganische membranen und verfahren für die herstellung von anorganischen membranen.
ATE223400T1 (de) Verfahren und zwischenprodukte zur herstellung von 4-trifluoromethylbiphenyl-2-carbonsaüre,(2- (2h-(1,2,4) triazol-3-ylmethyl)-1,2,3,4- tetrahydro-isoquinolin-6-yl)-amide
DE632163T1 (de) Verfahren zur Herstellung von porösen Geweben für Aufgussbeutel, und hergestellte Gewebe.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition